SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-003471
Filing Date
2023-01-12
Accepted
2023-01-12 17:13:17
Documents
12
Period of Report
2023-01-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm233167d1_8k.htm   iXBRL 8-K 34012
  Complete submission text file 0001104659-23-003471.txt   212116

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vyne-20230112.xsd EX-101.SCH 3060
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20230112_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20230112_pre.xml EX-101.PRE 22613
6 EXTRACTED XBRL INSTANCE DOCUMENT tm233167d1_8k_htm.xml XML 3707
Mailing Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 23526582
SIC: 2834 Pharmaceutical Preparations